Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; immersive virtual reality and display system that displays and tracks upper-extremity rehabilitation exercises under the REAL Immersive System brand name; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand name, as well as a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and POD Packing Coil brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.
IPO Year: 2015
Exchange: NYSE
Website: penumbrainc.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/14/2025 | $320.00 | Buy | BofA Securities |
| 1/21/2025 | $305.00 | Buy | UBS |
| 12/17/2024 | $275.00 | Outperform | Oppenheimer |
| 12/11/2024 | $190.00 → $275.00 | Equal Weight → Overweight | Wells Fargo |
| 9/18/2024 | $238.00 | Buy | Stifel |
| 9/3/2024 | $263.00 | Outperform | Leerink Partners |
| 7/31/2024 | $289.00 → $150.00 | Overweight → Equal Weight | Wells Fargo |
| 7/31/2024 | $165.00 → $178.00 | Buy → Neutral | Citigroup |
| 2/23/2024 | $284.00 → $250.00 | Overweight → Neutral | JP Morgan |
| 9/6/2023 | $265.00 | Equal-Weight | Morgan Stanley |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Penumbra Inc (0001321732) (Issuer)
4 - Penumbra Inc (0001321732) (Issuer)
4 - Penumbra Inc (0001321732) (Issuer)
4 - Penumbra Inc (0001321732) (Issuer)
4 - Penumbra Inc (0001321732) (Issuer)
4 - Penumbra Inc (0001321732) (Issuer)
4 - Penumbra Inc (0001321732) (Issuer)
4 - Penumbra Inc (0001321732) (Issuer)
4 - Penumbra Inc (0001321732) (Issuer)
4 - Penumbra Inc (0001321732) (Issuer)
Fastest customizable press release news feed in the world
10-Q - Penumbra Inc (0001321732) (Filer)
8-K - Penumbra Inc (0001321732) (Filer)
SD - Penumbra Inc (0001321732) (Filer)
8-K - Penumbra Inc (0001321732) (Filer)
144 - Penumbra Inc (0001321732) (Subject)
10-Q - Penumbra Inc (0001321732) (Filer)
8-K - Penumbra Inc (0001321732) (Filer)
DEFA14A - Penumbra Inc (0001321732) (Filer)
DEF 14A - Penumbra Inc (0001321732) (Filer)
PRE 14A - Penumbra Inc (0001321732) (Filer)
ALAMEDA, Calif., Aug. 20, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and times listed below. Event: 2025 Wells Fargo Healthcare Conference Date: Wednesday, September 3, 2025 Time: 8:45am ET/5:45am PT Event: Morgan Stanley 23rd Annual Global Healthcare Conference Date: Tuesday, September 9, 2025 Time: 1:50pm ET/10:50am PT Webcasts of the presentations can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's
ALAMEDA, Calif., July 30, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. Event: Canaccord Genuity 45th Annual Growth Conference Date: Tuesday, August 12, 2025 Time: 12:30pm ET/9:30am PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcast will be available on the company's website for at least two weeks followi
ALAMEDA, Calif., July 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2025. Revenue of $339.5 million in the second quarter of 2025, an increase of 13.4% or 12.7% in constant currency1, compared to the second quarter of 2024.U.S. Thrombectomy revenue of $188.5 million in the second quarter of 2025, an increase of 22.6% compared to the second quarter of 2024. U.S. VTE revenue increased 42% compared to the same period a year ago.Income from operations of $40.8 mil
ALAMEDA, Calif., July 1, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2025 after market close on Tuesday, July 29, 2025 at 4:30 PM Eastern Time. A press release with second quarter 2025 financial results will be issued after market close that day. Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the "
STORM-PE is a first-of-its-kind clinical trial comparing computer assisted vacuum thrombectomy (CAVT™) using Penumbra's Lightning Flash™ with anticoagulation versus anticoagulation alone in the treatment of acute intermediate-high risk pulmonary embolism ALAMEDA, Calif., June 16, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, announced the completion of enrollment in the STORM-PE clinical trial. The pivotal, prospective, multi-center randomized controlled trial enrolled 100 patients to evaluate computer assisted vacuum thrombectomy (CAVT) using Penumbra's Lightning Flash™ plus anticoagulation, versus anticoagulation alone, for the treatment of acute
ALAMEDA, Calif., June 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) announced the U.S. Food and Drug Administration (FDA) clearance and launch of the Ruby® XL System, the longest, largest and softest coil on the marketi. The Ruby XL System is designed to help physicians achieve more efficient embolization, potentially reducing radiation exposure, and optimizing outcomes — especially in large vessel and high-flow embolizationii. "We've engineered Ruby XL to deliver more volume per coil than any other coil on the market, which may result in cost savings," said Shruthi Naraya
ALAMEDA, Calif., May 20, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and times listed below. Event: William Blair 45th Annual Growth Stock Conference Date: Tuesday, June 3, 2025 Time: 3:00pm ET/12:00pm PT Event: Jefferies Global Healthcare Conference Date: Wednesday, June 4, 2025 Time: 9:55am ET/6:55am PT Event: Truist Securities MedTech Conference Date: Tuesday, June 17, 2025 Time: 10:00am ET/7:00am PT Webcasts of the presentations can be accesse
ALAMEDA, Calif., April 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Event: BofA Securities 2025 Health Care ConferenceDate: Tuesday, May 13, 2025Time: 6:00pm ET/3:00pm PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcast will be available on the company's website for at least two weeks followi
ALAMEDA, Calif., April 23, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025. Revenue of $324.1 million in the first quarter of 2025, an increase of 16.3% or 16.9% in constant currency1, compared to the first quarter of 2024.U.S. Thrombectomy revenue of $187.9 million in the first quarter of 2025, an increase of 25.0% compared to the first quarter of 2024.Income from operations of $40.4 million or operating margin of 12.4% in the first quarter of 2025.Net income
ALAMEDA, Calif., April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time. A press release with first quarter 2025 financial results will be issued after market close that day. Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the
Live finance-specific insights
ALAMEDA, Calif., July 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2025. Revenue of $339.5 million in the second quarter of 2025, an increase of 13.4% or 12.7% in constant currency1, compared to the second quarter of 2024.U.S. Thrombectomy revenue of $188.5 million in the second quarter of 2025, an increase of 22.6% compared to the second quarter of 2024. U.S. VTE revenue increased 42% compared to the same period a year ago.Income from operations of $40.8 mil
ALAMEDA, Calif., July 1, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2025 after market close on Tuesday, July 29, 2025 at 4:30 PM Eastern Time. A press release with second quarter 2025 financial results will be issued after market close that day. Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the "
ALAMEDA, Calif., April 23, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025. Revenue of $324.1 million in the first quarter of 2025, an increase of 16.3% or 16.9% in constant currency1, compared to the first quarter of 2024.U.S. Thrombectomy revenue of $187.9 million in the first quarter of 2025, an increase of 25.0% compared to the first quarter of 2024.Income from operations of $40.4 million or operating margin of 12.4% in the first quarter of 2025.Net income
ALAMEDA, Calif., April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time. A press release with first quarter 2025 financial results will be issued after market close that day. Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the
ALAMEDA, Calif., Feb. 18, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2024. Financial Highlights: Adjusted revenue1 of $321.3 million, excluding the $5.8 million impact of the Italian government's payback provision pertaining to prior years, an increase of 12.9% adjusted2 or 13.0% in adjusted constant currency2 compared to the fourth quarter of 2023.Adjusted revenue1 of $1,200.4 million, excluding the $5.8 million impact of the Italian governme
ALAMEDA, Calif., Jan. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2024 after market close on Tuesday, February 18, 2025 at 4:30 PM Eastern Time. A press release with fourth quarter and full year 2024 financial results will be issued after market close that day. Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 5872954), or the webcast can be accessed on the "Events and P
ALAMEDA, Calif., Oct. 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2024. Revenue of $301.0 million in the third quarter of 2024, an increase of 11.1% or 10.9% in constant currency1, compared to the third quarter of 2023.U.S. thrombectomy revenue of $162.1 million in the third quarter of 2024 increased 21.2% and 5.4% compared to the third quarter of 2023 and second quarter of 2024, respectively, led by growth in our U.S. VTE franchise, which grew 32% compa
ALAMEDA, Calif., Oct. 2, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2024 after market close on Wednesday, October 30, 2024 at 4:30 PM Eastern Time. A press release with third quarter 2024 financial results will be issued after market close that day. Webcast & Conference Call Information The conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 5872954), or the webcast can be accessed on the "Events and Presentations" section under t
ALAMEDA, Calif., July 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2024. Revenue of $299.4 million in the second quarter of 2024, an increase of 14.5% or 14.7% in constant currency1, compared to the second quarter of 2023.U.S. thrombectomy revenue of $153.7 million in the second quarter of 2024 increased 24.9% compared to the second quarter of 2023.Loss from operations of $81.0 million, which includes $110.3 million of one-time non-cash imp
ALAMEDA, Calif., July 2, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2024 after market close on Tuesday, July 30, 2024 at 4:30 PM Eastern Time. A press release with second quarter 2024 financial results will be issued after market close that day. Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 5872954), or the webcast can be accessed on the "Events and Presentations" section under the "
Live Leadership Updates
Campaign is led by prominent medical societies to minimize discrepancies in treating blood clot conditions, such as in pulmonary embolism, where there are often delays in care (up to 26% of patients in one study) and misdiagnosis (up to 53% of patients in one study)1,2 ALAMEDA, Calif., Oct. 10, 2024 /PRNewswire/ -- The International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra, Inc. (NYSE:PEN), The PERT Consortium™ and Society for Vascular Medicine (SVM) today announced the launch of the Get Out the Clot campaign in advance of World Thrombosis Day on October 13. The campaign is a collaborative educational initiative focused on identifying gaps i
SYDNEY, Australia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Omniscient Neurotechnology, the brain mapping company creating new possibilities in brain health, today announced the appointment of Barbara Nelson and Surbhi Sarna to its board of directors. Both appointees are visionaries across the biotech, healthcare and technology industries and bring a unique perspective to the company's corporate strategy and growth. They, along with the existing board members, will strategically guide Omniscient as it develops products that unlock new insights into advanced brain care. "Omniscient is a global leader in connectomics, but we have much work ahead of us to scale to our full potential," said Chairma
This live feed shows all institutional transactions in real time.
SC 13G/A - Penumbra Inc (0001321732) (Subject)
SC 13G/A - Penumbra Inc (0001321732) (Subject)
SC 13G - Penumbra Inc (0001321732) (Subject)
SC 13G/A - Penumbra Inc (0001321732) (Subject)
SC 13G/A - Penumbra Inc (0001321732) (Subject)
SC 13G/A - Penumbra Inc (0001321732) (Subject)
SC 13G/A - Penumbra Inc (0001321732) (Subject)
SC 13G/A - Penumbra Inc (0001321732) (Subject)
SC 13G/A - Penumbra Inc (0001321732) (Subject)
SC 13G/A - Penumbra Inc (0001321732) (Subject)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
BofA Securities initiated coverage of Penumbra with a rating of Buy and set a new price target of $320.00
UBS initiated coverage of Penumbra with a rating of Buy and set a new price target of $305.00
Oppenheimer initiated coverage of Penumbra with a rating of Outperform and set a new price target of $275.00
Wells Fargo upgraded Penumbra from Equal Weight to Overweight and set a new price target of $275.00 from $190.00 previously
Stifel initiated coverage of Penumbra with a rating of Buy and set a new price target of $238.00
Leerink Partners initiated coverage of Penumbra with a rating of Outperform and set a new price target of $263.00
Wells Fargo downgraded Penumbra from Overweight to Equal Weight and set a new price target of $150.00 from $289.00 previously
Citigroup downgraded Penumbra from Buy to Neutral and set a new price target of $178.00 from $165.00 previously
JP Morgan downgraded Penumbra from Overweight to Neutral and set a new price target of $250.00 from $284.00 previously
Morgan Stanley initiated coverage of Penumbra with a rating of Equal-Weight and set a new price target of $265.00